CD4 and rheumatoid arthritis: Anti-TNFα treatment results in a decrease of CD4+CD25+ cells in AS patients [18]; however, in RA patients, it restores CD4+ CD25+ cells to the level of healthy controls [19], while in patients with inflammatory bowel disease, it has no effect on blood levels of these cells [20].